liveBook · Manning

Virtual screening

As explained in Build AI Drug Discovery Pipelines

Virtual screening is computational prioritization of chemical compounds as drug candidates by predicting target interactions or drug-relevant properties.

Virtual screening uses computational methods to prioritize compounds as potential drug candidates. It narrows a large chemical library to a subset for experimental testing, based on predicted target interactions or properties such as solubility and toxicity. section 1.3.1 section 2.0

The goal is enrichment: retrieving a higher proportion of active compounds early than random selection would. Virtual screening can assess compounds that have not yet been synthesized, but it relies on a computational model or rules rather than producing experimental measurements. section 2.0

A screening pipeline often starts with inexpensive methods and applies more demanding ones to a smaller set. Machine learning is one option, not a requirement; simpler methods also provide useful comparison points. section 2.1.1

A possible hierarchy is:

  • Filter compounds for drug-likeness, structural alerts, or desired properties. section 2.1.1
  • Use ligand-based screening, such as a pharmacophore or machine-learning approach, to narrow the library further. section 2.1.1
  • Apply molecular docking to investigate binding in a target’s binding pocket, then molecular dynamics to a still smaller set. These stages are more computationally expensive. section 1.3.1 section 2.1.1
Figure 2.1 Virtual screening pipelines are often hierarchical, proceeding with a broad, large number of compounds through simpler, less restrictive, and computationally cheaper processes to whittle down the quantity of compounds. If the 3D structure of the target is not defined, we’re restricted to ligand-based virtual screening. If it is defined, then we can explore structure-based virtual screening, potentially as a downstream component to ligand-based virtual screening.

The pipeline diagram shows how screening stages narrow a library and how the availability of a target’s 3D structure affects the choice of strategy. section 2.1.1

The available data also guides method choice. In ligand-based screening, examples with and without the property of interest make classification with machine learning possible; when only positive examples are available, search-based strategies are more appropriate. section 2.1.1

Screening for desirable properties

To prioritize soluble, low-toxicity candidates, train a model using sufficient high-quality experimental data for those properties, then apply it to a candidate library. Such data is not always available, so the approach depends on checking the evidence before choosing a model. section 1.3.1

Finding potential antimalarial compounds

Compound filtering and similarity searching can be used to identify potential antimalarial hits. A separate machine-learning workflow for cardiotoxicity prediction illustrates data cleaning, molecular representation, model training, and evaluation. section 2.0 section 3.0

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Explains hierarchical screening choices and an end-to-end machine-learning workflow, while deferring detailed docking and molecular dynamics.
Examples
Uses antimalarial hit identification, solubility and toxicity prediction, and a cardiotoxicity modeling workflow.
What it assumes
Introduces molecular representation and machine-learning foundations for readers from chemistry or data-science backgrounds.
What you can do after
Evaluate screening strategies against available data, computational cost, and enrichment over random selection.
How it connects
Connects compound filtering, similarity search, machine learning, molecular docking, and molecular dynamics in screening pipelines.

Related concepts

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.